News & Articles

The cobas Malaria test is the first FDA-approved molecular test to screen US blood donors for malaria

The test detects T-cell response, which may play an important role in determining if immune protection has been achieved

The VENTANA DP 600 is Roche’s new, high-capacity slide scanner that creates high-resolution, digital images of stained tissue samples that help to diagnose cancer and determine a patient’s treatment

The AVENIO Tumor Tissue Comprehensive Genomic Profiling Kit is the first jointly-developed product that brings together the expertise and reach of Roche with Foundation Medicine’s pioneering leadership in genomic science

The VENTANA PD-L1 (SP263) Assay helps determine which non-small cell lung cancer patients may benefit from treatment with Tecentriq immunotherapy based on the results of the Phase III IMpower010 study

The three new respiratory test panels on cobas 6800/8800 Systems in CE markets will help identify multiple pathogens with overlapping symptoms in patients

Using cancer biomarkers, the VENTANA MMR RxDx Panel helps determine which tumor patients may benefit from GSK immunotherapy

The drug aims to treat patients with myelodysplastic syndromes

The authorization enables emergency use of Actemra/RoActemra for the treatment of COVID-19 in hospitalized adult and pediatric patients

The test will be widely available to individuals through pharmacies and other locations in accordance with local guidelines and testing strategies

First commercial test will enable expedited coronavirus testing to meet urgent medical needs